FibroGen

FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The Company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat, is an oral small molecule inhibitor of HIF prolyl hydroxylases in Phase 3 clinical development for the treatment of anemia in chronic kidney disease.

FibroGen's second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.

Company Growth (employees)
Type
Public
HQ
San Francisco, US
Founded
1993
Size (employees)
364 (est)
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St

FibroGen Financials and Metrics

FibroGen Financials

FibroGen's revenue was reported to be $26.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

26.9 m

Net income (Q1, 2017)

(33.2 m)

EBIT (Q1, 2017)

(31.4 m)

Market capitalization (17-Oct-2017)

3.9 b

Cash (31-Mar-2017)

170.6 m
FibroGen's current market capitalization is $3.9 b.
USDFY, 2015FY, 2016

Revenue

180.8 m179.6 m

Revenue growth, %

(1%)

R&D expense

214.1 m187.2 m

General and administrative expense

44.4 m46 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m
USDFY, 2015FY, 2016

Cash

153.3 m173.8 m

Accounts Receivable

15.4 m10.4 m

Inventories

4 m2.9 m

Current Assets

200.6 m266.5 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m

PP&E

131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m
USDFY, 2015FY, 2016

Net Income

(85.8 m)(61.7 m)

Depreciation and Amortization

5.7 m6 m

Accounts Receivable

(2 m)5 m

Inventories

978 k1.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(46.4 m)57.1 m(45.1 m)(27.8 m)24.3 m(24.2 m)(33.2 m)

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m

Accounts Payable

2.4 m3.9 m4.2 m1.5 m3.5 m2 m3 m
USDY, 2017

Revenue/Employee

73.9 k

Financial Leverage

3.4 x
Show all financial metrics

FibroGen Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

1

Facilities

2

Patent Portfolios

4
Show all operating metrics

FibroGen Market Value History

FibroGen Revenue Breakdown

Traffic Overview of FibroGen

FibroGen Online and Social Media Presence

FibroGen Company Life and Culture

You may also be interested in